Trial · NCT06210269
Oral Antibiotic Outpatient Therapy vs. Placebo in the Treatment of Uncomplicated Acute Appendicitis
NCT06210269, Not applicable, Not yet recruiting, Turku University Hospital
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Oral Antibiotic Outpatient Therapy vs. Placebo in the Treatment of Uncomplicated Acute Appendicitis. Trials, record NCT06210269. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT06210269
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Oral Antibiotic Outpatient Therapy vs. Placebo in the Treatment of Uncomplicated Acute Appendicitis
- NCT number
- NCT06210269
- Status
- Not yet recruiting
- Phases
- Not applicable
- Enrollment
- 498 participants, estimated
- Lead sponsor
- Turku University Hospital
- Conditions
- Uncomplicated Acute Appendicitis
- Interventions
- Moxifloxacin 400mg, Placebo
- First posted
- 2024-01-18
- Last updated
- 2024-01-18
Source ClinicalTrials.gov
Registered outcomes12
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Treatment success. | 30 days after treatment initiation | The primary outcome is 30-day treatment success defined similarly as in the previous trials, i.e. resolution of acute appendicitis resulting in discharge from the hospital without appendectomy during the 30-day follow-up. |
| Secondary | Post-intervention complications | 20 years | Complications according to the Clavien-Dindo classification |
| Secondary | Late recurrence of appendicitis | 20 years | Recurrence of acute appendicitis after the 30-day follow-up. |
| Secondary | Hospital stay | 20 years | Duration of hospital stay in hours |
| Secondary | Admission to hospital | 20 years | Admission to hospital and reason for admission, readmissions to emergency department or hospitalization. |
| Secondary | VAS score (visual analogue score) | 20 years | Pain defined by VAS pain score (scale 0-10, 0 equals no pain and 10 maximum pain imaginable) |
| Secondary | Quality of life EQ-5D-5L | 20 years | Quality of life (QOL, EQ-5D-5L). The descriptive system comprises five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems and extreme problems. The patient is asked to indicate his/her health state by ticking the box next to the most appropriate statement in each of the five dimensions. This decision results in a 1-digit number that expresses the level selected for that dimension. The digits for the five dimensions can be combined into a 5-digit number that describes the patient's health state. |
| Secondary | Sick leave | 20 years | Duration of sick leave in days |
| Secondary | Treatment costs | 20 years | Overall treatment and societal costs. |
| Secondary | Prognostic factors predicting initial unresponsiveness or recurrent appendicitis | 20 years | Potential prognostic factors predicting initial unresponsiveness to the randomized treatment as well as recurrent appendicitis |
1 to 10 of 12Source ClinicalTrials.gov
See all 12 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 39636024 | DERIVED |
Source PubMed
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT06210269
GET https://conductscience.org/api/trials/v1/NCT06210269/registered